Accentia Strikes $1.25M Deal To End Investors' Vaccine Suit
An Accentia Biopharmaceuticals Inc. subsidiary agreed Friday to pay $1.25 million to settle a putative securities class action in Florida federal court accusing the company of lying to investors about the...To view the full article, register now.
Already a subscriber? Click here to view full article